Literature DB >> 21414930

Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats.

John W Muschamp1, Ashlee Van't Veer, Aram Parsegian, Miranda S Gallo, Melissa Chen, Rachael L Neve, Edward G Meloni, William A Carlezon.   

Abstract

Stress triggers psychiatric conditions including depressive and anxiety disorders. The mechanisms by which stress produces persistent changes in behavior are not fully understood. Here we show in rats that stress (footshock) activates the transcription factor cAMP response element binding protein (CREB) within the nucleus accumbens shell (NAS), a brain area involved in encoding reward and aversion. To examine the behavioral significance of altered CREB function in the NAS, we used viral vectors to elevate or disrupt CREB in this region. Elevated CREB produced increases in intracranial self-stimulation thresholds, a depressive-like sign reflecting anhedonia (decreased sensitivity to reward), whereas disruption of CREB function by expression of a dominant-negative CREB had the opposite effect. To determine whether neuroadaptations that produce anhedonia subsequently affect vulnerability to stress-induced behavioral adaptations, we subjected rats with altered CREB function in the NAS to fear conditioning. Although neither elevation nor disruption of CREB function altered the development of conditioned fear, elevation of CREB impaired extinction of conditioned fear. To mimic downstream effects of CREB activation on expression of the opioid peptide dynorphin, we microinjected the κ-opioid receptor (KOR) agonist U50,488 directly into the NAS. KOR stimulation produced anhedonia but had no effect on expression or extinction of conditioned fear. These findings demonstrate that activation of CREB in the NAS produces multiple behavioral signs (anhedonia, impaired extinction) characteristic of experience-dependent psychiatric conditions such as posttraumatic stress disorder. Although CREB activation is a common trigger, expression of these individual signs appears to involve divergent downstream mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414930      PMCID: PMC3096840          DOI: 10.1523/JNEUROSCI.5973-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli.

Authors:  Michel Barrot; Jocelien D A Olivier; Linda I Perrotti; Ralph J DiLeone; Olivier Berton; Amelia J Eisch; Soren Impey; Daniel R Storm; Rachael L Neve; Jerry C Yin; Venetia Zachariou; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-06       Impact factor: 11.205

2.  Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation.

Authors:  William A Carlezon; Elena H Chartoff
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 3.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

4.  Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Authors:  Allison T Knoll; Edward G Meloni; James B Thomas; F Ivy Carroll; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2007-09-06       Impact factor: 4.030

Review 5.  Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis.

Authors:  William A Carlezon; Mark J Thomas
Journal:  Neuropharmacology       Date:  2008-07-15       Impact factor: 5.250

6.  Association of different adverse life events with distinct patterns of depressive symptoms.

Authors:  Matthew C Keller; Michael C Neale; Kenneth S Kendler
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

7.  Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens.

Authors:  Jennifer A Dinieri; Christina L Nemeth; Aram Parsegian; Tiffany Carle; Vsevolod V Gurevich; Eugenia Gurevich; Rachael L Neve; Eric J Nestler; William A Carlezon
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

8.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

9.  Differential regulation of prohormone convertase 1/3, prohormone convertase 2 and phosphorylated cyclic-AMP-response element binding protein by short-term and long-term morphine treatment: implications for understanding the "switch" to opiate addiction.

Authors:  V Paez Espinosa; Y Liu; M Ferrini; A Anghel; Y Nie; P V Tripathi; R Porche; E Jansen; R C Stuart; E A Nillni; K Lutfy; T C Friedman
Journal:  Neuroscience       Date:  2008-08-09       Impact factor: 3.590

10.  Attention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase within the medial prefrontal cortex of rats.

Authors:  Tracie A Paine; Rachael L Neve; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2009-04-22       Impact factor: 7.853

View more
  53 in total

1.  Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal.

Authors:  Anna K Radke; Jonathan C Gewirtz
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

2.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

3.  Thy1-expressing neurons in the basolateral amygdala may mediate fear inhibition.

Authors:  Aaron M Jasnow; David E Ehrlich; Dennis C Choi; Joanna Dabrowska; Mallory E Bowers; Kenneth M McCullough; Donald G Rainnie; Kerry J Ressler
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

4.  Optogenetic stimulation of accumbens shell or shell projections to lateral hypothalamus produce differential effects on the motivation for cocaine.

Authors:  Erin B Larson; Anne M Wissman; Amy L Loriaux; Saïd Kourrich; David W Self
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

Review 5.  Transcriptional Regulation Involved in Fear Memory Reconsolidation.

Authors:  Xu Wang; Min Li; Haitao Zhu; Yongju Yu; Yuanyuan Xu; Wenmo Zhang; Chen Bian
Journal:  J Mol Neurosci       Date:  2018-05-23       Impact factor: 3.444

6.  Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state.

Authors:  Yossef Goffer; Duo Xu; Sarah E Eberle; James D'amour; Michelle Lee; David Tukey; Robert C Froemke; Edward B Ziff; Jing Wang
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

7.  Role of medial prefrontal cortex Narp in the extinction of morphine conditioned place preference.

Authors:  Ashley M Blouin; Sungho Han; Anne M Pearce; Kailun Cheng; Jongah J Lee; Alexander W Johnson; Chuansong Wang; Matthew J During; Peter C Holland; Yavin Shaham; Jay M Baraban; Irving M Reti
Journal:  Learn Mem       Date:  2013-01-15       Impact factor: 2.460

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

10.  AMPAkines Target the Nucleus Accumbens to Relieve Postoperative Pain.

Authors:  Chen Su; Hau Yeuh Lin; Runtao Yang; Duo Xu; Michelle Lee; Natalie Pawlak; Monica Norcini; Alexandra Sideris; Esperanza Recio-Pinto; Dong Huang; Jing Wang
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.